DAYBREAK is a prospective, multi-omics, observational study aimed at early detecting pancreatic cancer by combined assays for biomarkers of cfDNA methylation, serum protein markers, blood miRNA markers and others, in which of 450 participants will be enrolled. The development and validation of the model will be conducted in participants with early stage cancers and benign disease through a two-stage approach. The sensitivity and specificity of the model in pancreatic cancer early detection will be evaluated.
Study Type
OBSERVATIONAL
Enrollment
450
Shanghai Changhai Hospital
Shanghai, Shanghai Municipality, China
RECRUITINGThe sensitivity and specificity of multi-cancer early detection by the combined model in cancer arm and benign disease arm
Time frame: 12 months
The difference of sensitivity and specificity in pancreatic cancer participants at different clinical stages.
Time frame: 12 months
Sensitivity and specificity for detecting pancreatic cancer of a cfDNA methylation-based model, in combination with other biomarkers.
Time frame: 12 months
Sensitivity and specificity for detecting pancreatic cancer of a the protein panel-based model, in combination with other biomarkers.
Time frame: 12 months
Sensitivity and specificity of the blood miRNA-based model in detecting pancreatic cancer.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.